IFP Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

IFP Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.14M	Buy	361,634 +33,843	+10%	+$541K	0.11%	204
2026 Q1	$4.86M	Buy	327,791 +53,105	+19%	+$776K	0.1%	225
2025 Q4	$4.38M	Buy	274,686 +11,834	+5%	+$168K	0.1%	219
2025 Q3	$2.9M	Buy	262,852 +2,818	+1%	+$30.8K	0.08%	288
2025 Q2	$2.2M	Sell	260,034 -17,546	-6%	-$141K	0.06%	335
2025 Q1	$2.23M	Buy	277,580 +6,448	+2%	+$52.2K	0.07%	334
2024 Q4	$2.43M	Buy	271,132 +64,107	+31%	+$523K	0.08%	284
2024 Q3	$1.52M	Buy	+207,025	New	+$1.28M	0.05%	370
2023 Q1	–	Sell	-265	Closed	-$2K	–	3422
2022 Q4	$2K	Buy	265 +65	+33%	+$377	﹤0.01%	4111
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	4500
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	4277
2022 Q1	$1K	Buy	+200	New	+$3.09K	﹤0.01%	4277
2017 Q2	–	Sell	-1,000	Closed	-$7K	–	4075
2017 Q1	$7K	Buy	+1,000	New	+$4.62K	﹤0.01%	3098

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's AUPH Position: Q2 2026 in Review

IFP Advisors increased its Aurinia Pharmaceuticals (AUPH) stake by 10% in Q2 2026, buying an estimated $541K and bringing the position to 361,634 shares worth $6.14M. The position accounts for 0.11% of the portfolio, ranked #204.

IFP Advisors first reported a position in AUPH in Q1 2017 and has held it in 13 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

IFP Advisors held 361,634 shares of Aurinia Pharmaceuticals worth $6.14M as of Q2 2026.
IFP Advisors bought 33,843 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $541K.
Aurinia Pharmaceuticals made up 0.11% of IFP Advisors's portfolio in Q2 2026, its #204 holding.
IFP Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 13 quarters since.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.